Enzyme-linked immunosorbent assay for variable region .LAMBDA. VI subgroup of light chain in serum: method and results in normal subjects and patients with hyper- and hypogammaglobulinemia.:method and results in normal subjects and patients with hyper-and

スポンサーリンク

概要

• 論文の詳細を見る

• We have established a simple, sensitive and reproducible sandwich enzyme-linked immunosorbent assay (ELISA) for quantitation of immunoglobulins of λ VI subgroup (Ig λ VI) which has been of special interest by its amyloidogenicity. It used murine monoclonal antibodies specific for λ VI subgroup of variable region (VL) and for λ type of constant region (CL) of human immunoglobulin light chains. The λ VI protein level and the percent distribution of λ VI subgroup among total Igλ proteins (λ VI/λ ratio) in serum were determined. Igλ VI proteins were contained in each of serum specimens tested. In serum specimens obtained from 44 normal subjects and 14 patients with polyclonal hypergammaglobulinemia and six patients with hypogammaglobulinemia, the concentration (mean±SD) of Igλ VI proteins was 78 to 432 (197±81), 218 to 1875 (648±474) and 49 to 115 (85±25) μg/ml and that of total Igλ proteins was 2, 640 to 8, 300 (4, 712±1, 454), 8, 197 to 30, 000 (14, 837±7, 029) and 890 to 1, 800 (1312±340) μg/ml, and the λ VI/λ ratio (mean±SD) was 1.2 to 9.4 (4.3±1.7), 2.1 to 6.4 (4.2±1.7) and 4.6 to 9.2 (6.5±1.6)%, respectively. The λ VI/λ ratio was strikingly higher than 10% in serum specimens from three patients with λ VI-related amyloidosis, which implied clinical and diagnostic availability of this ratio. In patients with rheumatoid arthritis, systemic lupus erythematosus and liver cirrhosis presenting polyclonal hypergammaglobulinemia, λ VI proteins were contained at high concentration in serum, but no amyloid deposition was found in biopsied specimens. However, further study on more cases with polyclonal Igλ VI protein overproduction is required to elucidate amyloidogenicity of non-malignant Igλ VI proteins. The assays described here will facilitate the study on monoclonal and polyclonal nature of this unique λ VI subgroup in various disease conditions.

• 日本臨床免疫学会の論文

著者

• 尾崎 修治

  徳島大学第1内科

• 後藤 哲也

  徳島大学第1内科

• 小阪 昌明

  徳島大学第1内科

• 安倍 正博

  徳島大学第1内科

• Solomon Alan

  The Human Immunology and Cancer Program, Department of Medicine, The University of Tennessee Medical Center

関連論文

• 90)巨大脾膿瘍を形成した腸球菌による感染性心内膜炎の一例(日本循環器学会 第79回中国四国地方会)
• 87) 右房内腫瘤による心不全に対し化学療法が奏功した非ホジキンリンパ腫の一例(日本循環器学会 第78回四国地方会)
• 多発性骨髄腫の骨吸収病変に対するビスフォスフォネートの効果
• 多発性骨髄腫におけるMIP-1の産生とその骨髄腫骨病変形成への関与
• 431 消化管原発 Burkittリンパ腫の一手術例(第18回日本消化器外科学会総会)
• (5)アクチビンおよびフォリスタチンの測定と臨床的意義
• ビスフォスフォネートによる骨転移の治療
• 免疫グロブリン異常症へのアプローチ
• 白血球減少をきたした「胸腺腫を伴う免疫不全症」の二例
• Autoantibody formation after alpha-interferon therapy to patients with myeloma.
• Enzyme-linked immunosorbent assay for variable region .LAMBDA. VI subgroup of light chain in serum: method and results in normal subjects and patients with hyper- and hypogammaglobulinemia.:method and results in normal subjects and patients with hyper-and
• Monoclonal plasmacytosis and its related diseases. Idiopathic (benign) monoclonal immunoglobulinemia.
• Analysis of myeloma cell surface antigen by new monoclonal antibody which recognizes plasma cell relevant antigen.

もっと見る 閉じる

スポンサーリンク